NeuroSense Therapeutics Ltd

NASDAQ:NRSN  
1.58
+0.07 (+4.64%)
Products

Neurosense Receives FDA Clearance Of IND For Its ALS Phase 2B Study

Published: 11/15/2022 14:24 GMT
NeuroSense Therapeutics Ltd (NRSN) - Neurosense Receives FDA Clearance of Ind for Its Als Phase 2b Study.
Neurosense Therapeutics- Paradigm Currently Enrolling Patients in Israel, Expects to Open Clinical Sites for Patient Recruitment in Eu in Coming Weeks.
Neurosense Therapeutics Ltd - Expects to Enroll and Dose First U.S. Patients in Next Few Weeks at Leading Als Centers on Both East and West Coast.